Jaguar Health Retires $5.05M of Debt via Share Issuance to Streeterville
JAGX has more than doubled off its 52-week low of $2.35 on elevated volume (18× avg).
Summary
Jaguar Health issued 547,898 shares to Streeterville Capital to retire $5.05 million of secured debt, cutting its cash obligations while significantly diluting existing shareholders. It also exchanged 182,091 shares to reduce its 2021 Note by $1,678,320.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Jaguar Health also exchanged 182,091 shares to cut $1,678,320 from its 2021 Note, leaving about 1,463,958 shares outstanding.
Key Events · Financing and Capital Events · JAGX
-
New · · SEC 8-K
2021 Note Exchange
Jaguar Health exchanged 182,091 shares to reduce its 2021 Note by $1,678,320.
-
Updated · · SEC 8-K
Dilution Impact
Post-exchange outstanding shares total approximately 1,281,867, meaning the new shares represent roughly 42.7% of the post-transaction share count. After the additional exchange of 182,091 shares, about 1,463,958 shares are outstanding.
-
Debt-for-Equity Exchange
Issued 547,898 shares to Streeterville Capital in exchange for a $5,049,909.26 reduction in the outstanding balance of the 2025 Note.
-
Implied Exchange Price
The exchange implies a price of approximately $9.21 per share ($5,049,909.26 ÷ 547,898 shares), above the current market price of $7.74.
-
Debt Reduction
The exchange reduces the $10.81 million 2025 Note by $5.05 million, leaving approximately $5.76 million outstanding.
Analysis · JAGX · Life Sciences
By converting $5.05 million of secured debt into equity at an implied price of roughly $9.21 per share, Jaguar Health reduces its cash obligations to Streeterville Capital. The exchange eliminates a meaningful portion of the $10.81 million 2025 Note while adding 547,898 shares to the float — a 42.7% increase over the 1,281,867 shares outstanding after the transaction. A further exchange of 182,091 shares cut $1,678,320 from the 2021 Note, leaving about 1,463,958 shares outstanding. For a company with only $3.8 million in cash and a going-concern warning, retiring debt without spending cash is a survival move, but the dilution is substantial for existing holders.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.8% of the 1640 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $7.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $2.35 to $1,280.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.